Hexa Reports Market Research Reports and Insightful Company Profiles
Cymbalta (Neuropathic Pain) Forecast and Market Analysis to 2022
Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile. Browse Detail Report With TOC @ http://www.hexareports.com/report/cymbalta-neuropathic-painforecast-and-market-analysis-to-2022/details Cymbalta (duloxetine) is an SNRI that was developed by Eli Lilly and was initially approved in the US in August 2004 for the treatment of major depressive disorder (MDD). The drug was later approved for PDN in September 2004. Since then, Eli Lilly has accrued multiple indications for Cymbalta, such as GAD,
Hexa Reports Market Research Reports and Insightful Company Profiles fibromyalgia, and most recently, for the treatment of chronic musculoskeletal pain, including chronic osteoarthritis pain and chronic low back pain. Scope
Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Cymbalta including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Cymbalta for the top seven countries from 2012 to 2022. Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Request a sample copy of this Report @ http://www.hexareports.com/sample/41955 Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Cymbalta performance Obtain sales forecast for Cymbalta from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan). Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 3 Disease Overview 3.1 Clinical Manifestations of Neuropathic Pain Signs and Symptoms 3.1.1 Painful Diabetic Neuropathy 3.1.2 Postherpetic Neuralgia 3.1.3 Trigeminal Neuralgia 3.2 Etiology and Pathophysiology 3.2.1 Etiology 18 3.2.2 Pathophysiology 4 Disease Management
Hexa Reports Market Research Reports and Insightful Company Profiles 4.1 Diagnosis and Treatment Overview 4.1.1 Diagnosis 4.1.2 Treatment Overview and Guidelines 5 Competitive Assessment 5.1 Overview Browse Full Report @ http://www.hexareports.com/report/cymbalta-neuropathic-pain-forecast-andmarket-analysis-to-2022/details
About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/